Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old
Status:
Withdrawn
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
This study is an 8-week open-label trial testing Lurasidone (Latuda®) as a treatment for
mania in children and adolescents with Bipolar I, Bipolar II, and Bipolar Spectrum disorders.
We hypothesize that Lurasidone will be safe, tolerable, and effective in improving the core
symptoms of bipolar disorders in children and adolescents ages 6-17.